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Abstract Candidemia is a major infectious complication in
neonatal patients. The isolation of yeasts from blood is still
the “gold standard” for its diagnosis, but other laboratory
markers (i.e., circulating antigens) have been studied with
varying specificities and sensitivities. The aim of this study
was to evaluate the role of procalcitonin for the diagnosis of
candidemia in neonatal patients at high risk. To verify if the
use of different commercial methods can highlight dissimi-
lar results of sensitivity and/or specificity, the determination
of procalcitonin serum levels was estimated by two systems.
Overall, 90 patients from a Neonatal Intensive Care Units
were enrolled, of whom six developed Candida bloodstream
infection. Four of six infants with candidemia had slight
increase of procalcitonin values (0.5–1 ng/mL). Only one
baby showed very high levels but he had fungal and bacte-
rial sepsis at the same time, while no elevation was observed
in the sixth patient. No statistically significant difference
was observed between two different methods at the time of
monitoring (p>0.643). Both methods showed a sensitivity
of 83.3 % at diagnosis, while the specificity was 73.8 and
63.1 % by methods A and B, respectively. In the light of the
low sensibility and specificity of this assay, we can assume
that the determination of procalcitonin would not seem to
play a significant role in the diagnosis of fungal infection in
neonatal patients.
Introduction
The neonates admitted in Neonatal Intensive Care Unit
(NICU) are highly prone to develop invasive fungal infections
(IFIs) as result of the mostly unavoidable presence of several
risk factors. The isolation of yeast from blood remains the
“gold standard” for the diagnosis of candidemia in these
patients, but it is hampered by small amount of blood that
can be drawn from neonates (Connell et al. 2007; Rabalais et
al. 1996; Smith and Congdon 1985), by nonspecific clinical
symptoms and by frequent unavailability of Candida isolates
from blood systems (their sensitivity for fungi may be as low
as 50 %; Benjamin et al. 2000, 2003). In addition, blood
cultures take some days to grow these organisms.
To date, other laboratory markers (C-reactive protein, Can-
dida mannan, 1→3-beta-D-glucan antigen, specific antibod-
ies, or DNA fungal detection) are currently considered as a
useful support to achieve an early diagnosis of deep mycoses.
However, some of these still require standardization and fur-
ther evaluation and are not affordable for all laboratories
because of various economic and technical reasons (Di
Stefano et al. 2004; Oliveri et al. 2008; Mularoni et al. 2010).
Procalcitonin (PCT) is the precursor of the hormone
calcitonin, normally produced by C-cells of the thyroid
gland in response to hormonal stimuli and virtually
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undetectable in healthy subjects (<0.5 ng/mL). In response
to inflammatory stimuli, the PCT can be also produced by
liver (Nijsten et al. 2000) and peripheral blood mononuclear
cells (Oberhoffer et al. 1999), increasing up to 1,000 ng/mL
in patients with systemic bacterial infections or septic shock
(Assicot et al. 1993; Meisner et al. 1999). Furthermore, it
might help to distinguish bacteremia from non-infectious
inflammatory conditions resulting in an important impact
on therapeutic decisions (Meisner 2002; Simon et al. 2004;
van Rossum et al. 2004; Schneider and Lam 2007; Becker et
al. 2008).
Regarding the role of PCT in IFIs, the literature data are still
few and controversial (Charles et al. 2009; Christofilopoulou et
al. 2002; Huber et al. 1997); mostly, late elevations of PCT
have been observed in patients with disseminated aspergillosis
(Beaune et al. 1998) and in some children with invasive candi-
diasis (Dornbusch et al. 2005). Recently, Martini et al. (2010),
studying the role of PCT in surgical patients with candidemia,
observed that low PCT levels (less than 2.0 ng/mL) were more
likely related to candidemia than bacteremia.
The aim of this study was to evaluate whether PCT may
be an additional marker for Candida-related sepsis in neo-
natal patients at high risk of candidemia. To verify if the use
of different commercial methods can highlight dissimilar
results of sensitivity and/or specificity, the determination
of PCT serum levels was estimated by two systems.
Material and methods
The eligible patients were preterm infants (gestational age,
<35 weeks) weighing ≤1,500 g at birth or full-term infants,
all showing at least one of following clinical signs: apnea
caused by respiratory stress, hypothermia, and tachycardia.
Infants delivered by mothers receiving antibiotics either
before or during delivery, not requiring intensive care, with
mucocutaneous candidiasis or with proven bacterial sepsis
were excluded from our study. Each enrolled patient was
subjected to serum PCT assay from the third day of life (T3)
and repeated on the fifth (T5), seventh (T7), ninth (T9), and
11th day (T11). Serum samples were kept refrigerated at
−70 °C until they were processed. At the same interval time
(T3, T5, T7, T9, and T11), blood cultures were carried out
and an electronic report form was completed including
clinical and microbiological data.
The determination of PCT serum levels was estimated in
duplicate in every assay and on the same day by two
systems: VIDAS® BRAHMS PCT (method A, bioMérieux,
France) and KRYPTOR® BRAHMS PCT (method B,
DASIT, Germany).
Method A is an automated test using the enzyme-linked
fluorescent assay technique. It combines a one-step immu-
noassay sandwich method with a final fluorescent detection
requiring 200 μL of serum per sample. Its measurement
range is 0.05–200 ng/mL.
Method B is a homogeneous assay (sandwich principle)
using TRACE® technology (time-resolved amplified crypt-
ate emission). The needed serum volume is limited to
50 μL. The measuring range is 0.02–50 ng/mL.
We considered PCT values <0.5 ng/mL to be negative,
ranging from 0.5 to 1.0 ng/mL moderately elevated, values
>1.0 ng/mL highly elevated. Blood cultures were performed
using a lyses centrifugation system (Isolator® DuPont Co,
Delaware), incubated at 36 °C (±1 °C) for 7 days. Identifi-
cation of yeasts was carried out by VITEK2 System (bio-
Mérieux, France).
The day of notification of presence of yeasts in the blood
culture was defined “infection day”. The data statistical
analysis was carried out using the software Statistical Pack-
age for Social Sciences. The model used to obtain the
significance of the averages during the time and among
the different specimens is the ANOVA model (the variance
analysis) which allowed us to calculate the F test and the p
value <0.05. We used the technique of multiple comparison
with the Tukey HSD model to analyze the significance of
differences among groups. The tests gave information on
which pairs of averages were significantly different, after a
significant difference between averages of the groups was
verified. Data for both methods were analyzed for sensitiv-
ity and specificity, negative predictive value (NPV) and
positive predictive value (PPV).
Results
During the 18-months study, 90 infants were enrolled from
NICU (Table 1), and a total of 447 sera were tested. Figure 1
shows the trend of 90 infants with PCT levels >0.5 ng/mL
tested by A and B methods in each time. We observed that at
time T3, the overall percentage of patients with PCT
>0.5 ng/mL was 27.7 % by the method A and 40 % by the
method B; these values progressively decreased until to
2.2 % at T7 and 0 % at T9 by both methods.
On the whole, six patients (6.6 %) developed a blood-
stream infection (BSI): three caused by Candida albicans
and three by Candida parapsilosis (Table 2). For each of
these patients, the blood cultures resulted positive only one
time during the period study. PCT values were slightly
increased only in four patients (no. 1–4) either 2 days before
or at diagnosis. Patient no. 5 showed very high values (17.1
and 7.02 ng/mL by methods A and B, respectively) but a
severe bacterial BSI was confirmed at the same time, with
an unfavorable outcome. For patient no. 6, the PCT values
resulted always <0.5 ng/mL, with the exception of the
assessment at the time T3 (0.62/0.53 ng/mL by A and B
methods, respectively).
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Considering the 84 uninfected newborns (Table 3), the
serum PCT levels (the mean value±SD) obtained with
method A were <0.5 ng/mL (0.26±0.09) in 62 patients and
>0.5 ng/mL (0.56±0.03) in 22 patients at time T3, <0.5 ng/
mL (0.23±0.09) in 77 infants and >0.5 ng/mL (0.53±0.02)
in seven infants at time T5. About the PCT levels obtained
by the method B, the values resulted <0.5 ng/mL (0.22±
0.07) in 53 patients and >0.5 ng/mL (0.54±0.03) in 31
patients at time T3, <0.5 ng/mL (0.20±0.08) in 73 infants
and >0.5 ng/ml (0.52±0.01) in 11 infants at time T5.
The PCT values tested at time T7, T9, and T11 resulted
always <0.5 ng/mL by the methods A and B in all the 84
uninfected patients. No statistically significant difference
was observed between two methods at the time of monitor-
ing (p>0.643). Considering a threshold PCT value of
0.5 ng/mL and analyzing the patients showing slightly in-
creased PCT, both methods showed a sensitivity of 83.3 %
at diagnosis, while the specificity was 73.8 and 63.1 % by
methods A and B, respectively. The NPV and PPV for the
method A were 18.5 and 98.4 % respectively; for the meth-
od B were 13.9 and 98.1 %, respectively.
Discussion
Although important progress is being made in the diagnosis
of fungal diseases, Candida BSI still represents a clinical
event of difficult resolution. In NICU patients, the early
detection of sepsis is difficult because the first signs of this
disease may be minimal or similar to those of non-infectious
processes. Furthermore, the results of blood cultures are not
quickly available and other laboratory tests lack high sensi-
tivity and specificity.
Recently, some authors have considered the PCT value as
a potential biological marker of fungal sepsis (Charles et al.
2009; Christofilopoulou et al. 2002; Martini et al. 2010).
Unfortunately, its role in diagnosis of these diseases has not
yet been elucidated, particularly regarding newborns: they
may exhibit elevated PCT levels because of a physiological
increase in the first days of life which revert to normal range
3–4 days after birth (Turner et al. 2006). This occurrence
could be caused by birth trauma or host response to the
initial establishment of the normal intestinal bacterial flora








≤1,000 (ELBWa) 14 (15.5)
1001–1500 (VLBWb) 76 (84.4)
Risk factors
Gestational age <35 weeks 87 (96.6)
Central venous catheter 76 (84.4)
Respiratory distress syndrome 75 (83.3)
Parenteral nutrition 54 (60.0)
Mechanical ventilation 21 (23.3)
Othersc 11 (12.2)
a Extremely low birth weight (body mass ≤1,000 g)
b Very low birth weight (body mass between 1,001 and 1,500 g)







































Fig. 1 Percentage of NICU
patients with PCT levels>
0.5 ng/mL in each time of
monitoring, tested by Vidas®
Brahms PCT, bioMérieux
(Method A) and Kryptor®
Brahms PCT, Dasit (Method B)
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or by the adaptation to the extra-uterine environment. These
phenomena stimulate an acute phase reaction with release of
C-reactive protein, interleukin-6, and serum amyloidal A
(Chiesa et al. 2001; Marchini et al. 2000). For this reason,
we excluded patients younger than 72 h from our research.
Our findings showed a slight increase of PCT values both
in some infants without fungal infections as in four out of
six infants with BSI. In the light of these results, it is
difficult to understand the role of PCT in the diagnosis of
Candida BSI in NICU patients. In fact, its low sensibility
and specificity leads us to consider that PCT determination
does not play a significant role in the diagnosis of these
infections respect to other diagnostic assays. In particular, in
another study, 1→3-beta-D-glucan (BDG) and Candida
mannan (CM) were tested in the same neonates with Can-
dida BSI only at the time as the positive blood cultures: in
all six patients, the BDG test resulted positive, while the CM
antigen resulted positive only in three patients with C.
albicans BSI (Montagna et al. 2011).
We are aware that this study presents the limitation of the
low number of patients with candidemia, but it is well
known that obtaining appropriate and seriated specimens
in neonatal patients is hampered by the critical conditions
of these patients and by small amount of blood that can be
drawn.
Regarding the two methods used to evaluate PCT levels, no
statistically significant differences was detected (p>0.05); nev-
ertheless, we want to underline some questions. If we consider
PCT values, <0.5 ng/mL to be negative and ranging from 0.5 to
1.0 ng/mL to bemoderately elevated and analyze the individual
values of PCT detected in any patient with candidemia, some
discrepancies can appear between the two methods. In fact, the
two systems employed at the same time and on the same serum
sample of two out of six infants with candidemia (patients no. 4
and 5) highlight negative or slightly positive values respective-
ly, posing a problem for the evaluation of PCT and interpreta-
tion of data: no fungal sepsis could be suspected for the infants
no. 4 and 5 at time T3 if we consider the PCT values obtained
by method A (0.44 and 0.22 ng/mL, respectively), but a doubt
appears in the same patients if we consider the PCT value
obtained by method B (0.68 and 0.57 ng/mL, respectively).
Therefore, in these two cases, the two methods do not lead to
the same clinical interpretation. Besides, for infant no. 4, the
PCT values obtained by both methods appear to differ also at
time T5 (0.59 and 0.84 ng/mL, respectively) and T7 (0.55 and
0.76 ng/mL, respectively). Perhaps, it could be useful to rec-
ognize an appropriate cutoff concentration for the fungal infec-
tions both to exclude false interpretations from use of different
commercial systems and to separate fungal infections from
bacterial ones.
Conclusions
Our data suggest that PCT assay do not play a significant
role in neonates with candidemia. We can assume that its
values from 0.5 to 1 ng/mL cannot be considered a reliable
indicator of fungal sepsis, as well as low values of PCT
cannot exclude this infection. We consider our results pre-
liminary data carried out in a single neonatal intensive care
unit planning to follow a line of a multicenter investigation.
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Table 2 PCT values in six
babies recovered in NICU with
Candida BSI tested by Vidas®
Brahms PCT, bioMérieux
(method A) and Kryptor®
Brahms PCT, Dasit (method B)
aInfection day (day of notification
of presence of yeasts in blood
culture)





T3 T5 T7 T9 T11
1/M 1,230 C. albicans 0.48/0.33 0.69/0.53 0.58/0.52a 0.48/0.16 0.40/0.30
2/M 630 C. parapsilosis 0.98/0.60 1.27/0.80a 0.49/0.48 0.35/0.30 0.37/0.23
3/F 800 C. albicans 0.57/0.51 0.83/0.54a 0.44/0.42 0.35/0.35 0.20/0.30
4/M 1,150 C. parapsilosis 0.44/0.68 0.59/0.84 0.55/0.76a 0.17/0.36 0.06/0.14
5/M 1,310 C. albicans/K.
pneumoniae
0.22/0.57 17.1/7.02a Died
6/F 1,130 C. parapsilosis 0.62/0.53 0.20/0.20 0.17/0.29 0.34/0.35a 0.22/0.18
Table 3 Number of NICU patients with PCT levels >0.5 and <0.5 ng/
mL in each time of monitoring, tested by Vidas® Brahms PCT, bio-
Mérieux (method A) and Kryptor® Brahms PCT, Dasit (method B)
PCT cut\-off value (ng/mL) Patients (no.)
Method A *T3 T5 T7 T9 T11
>0.5 22 7 − − −
<0.5 62 77 84 84 84
Method B
>0.5 31 11 − − −
<0.5 53 73 84 84 84
a T3, T5, T7, T9, and T11: times of PCT monitoring
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